Wen Wee Ma, MBBS | Authors


Current Management of Pancreatic Cancer

August 24, 2015

Recent therapeutic advances have almost doubled the survival of patients with metastatic pancreatic cancer, and the availability of highly active chemotherapy regimens is making personalized medicine a reality.

LDK378: A Promising Next-Generation ALK Inhibitor

January 08, 2014

LDK378 is a highly selective and potent inhibitor of ALK, and has demonstrated preclinical antitumor activity against tumors with acquired crizotinib resistance. In a phase I trial, LDK378 induced tumor response in 70% of patients with crizotinib-resistant NSCLC.